LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer

Dr. Chapin and fellow expert oncologists discuss the latest data from the LIGHTHOUSE trial, evaluating 18F-rhPSMA-7.3 for staging patients with prostate cancer.

EP: 1.The Evolution of Imaging Techniques in Prostate Cancer

EP: 2.The Utility of PSMA PET in Prostate Cancer

EP: 3.Clinical Development of PSMA-Targeted Therapies

EP: 4.Clinical Practices of PSMA-Targeted Agents in Prostate Cancer

EP: 5.Multidisciplinary Approaches in PSMA PET for Prostate Cancer

EP: 6.Patient Profile 1: A 51-Year-Old Man with High-Risk Localized Prostate Cancer

EP: 7.PSMA PET Imaging and Clinical Perspectives from Patient Profile 1

Now Viewing

EP: 8.LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer

EP: 9.An Overview of the SPOTLIGHT Trial for PSMA PET in Prostate Cancer

EP: 10.SPOTLIGHT Trial and 18F-rhPSMA-7.3 for Prostate Cancer

EP: 11.Patient Profile 2: A 62-Year-Old Man with Recurrent Prostate Cancer

EP: 12.Patient Profile 3: A 67-Year-Old Male with Recurrent Prostate Cancer

EP: 13.Future Horizons in PSMA-Targeted Imaging and the Management of Prostate Cancer

Related Videos

Related Content

Advertisement

February 24th 2025

Phase 1/2 trial launches of first-in-class RIPTAC therapeutic in mCRPC

Hannah Clarke

The trial plans to enroll up to 80 adult patients with mCRPC who have progressed on prior systemic therapies.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

February 14th 2025

Real-world studies underline safety, efficacy of radium-223 in mCRPC

Benjamin P. Saylor

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

February 14th 2025

Radium-223 re-treatment is safe in patients with mCRPC

Benjamin P. Saylor

The median number of re-injections was 6 (range, 1-12).

February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

Related Content

Advertisement

February 24th 2025

Phase 1/2 trial launches of first-in-class RIPTAC therapeutic in mCRPC

Hannah Clarke

The trial plans to enroll up to 80 adult patients with mCRPC who have progressed on prior systemic therapies.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

February 14th 2025

Real-world studies underline safety, efficacy of radium-223 in mCRPC

Benjamin P. Saylor

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

February 14th 2025

Radium-223 re-treatment is safe in patients with mCRPC

Benjamin P. Saylor

The median number of re-injections was 6 (range, 1-12).

February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.